---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040617"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:44:03.354483+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adicet Q2 net loss $32.4M; ADI-001 shows 71% ORR, 63% CR in Phase 1 NHL

## Summary
- Q2 net loss $32.4M ($0.75/share) vs $22.5M ($0.56) in Q2 2022; R&D expenses rose to $28.4M.
- ADI-001 Phase 1 data: 71% ORR, 63% CR across all dose levels in heavily pretreated NHL (median 4 prior lines); no DLTs/GvHD.
- Plan to initiate pivotal Phase 2 study in post-CAR T LBCL under accelerated approval in 2024; expansion cohort EXPAND starting.
- IND for ADI-925 (solid tumors) expected H2 2023; IND for ADI-270 (renal cell carcinoma) expected H1 2024.
- Cash $205.5M as of June 30, 2023; runway into H1 2025. Appointed Katie Peng to Board in July.

## SEC filing metadata
- accession: 0000950170-23-040617
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/0000950170-23-040617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/acet-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040617
- JSON: https://secwatch.observer/filing/0000950170-23-040617.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040617.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported the quarter ended June 30, 2023 results: net income $32.4 million, EPS $0.75 per basic and diluted share.
  - Period: the quarter ended June 30, 2023
  - Net income: $32.4 million
  - EPS: $0.75 per basic and diluted share
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023 was $32.4 million, or a net loss of $0.75 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017023040617/0000950170-23-040617-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.